Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

oxaliplatin / Generic mfg.

TORCH-C, NCT05732493: Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer

Not yet recruiting

120

Serplulimab, short-term radiotherapy, Shor-course radiotherapy: 25Gy/5Fx, Oxaliplatin, Capecitabine, Xeloda

Fudan University

Locally Advanced Colon Cancer

12/23

12/24

NCT05400902: HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

Recruiting

RoW

HAIC Combined with Tislelizumab and Apatinib

Binkui Li

Intrahepatic Cholangiocarcinoma

12/23

NCT05582278: HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

Recruiting

RoW

D-TACE, D-TACE+lenvatinib+tislelizumab, HAIC, HAIC+Lenvatinib+tislelizumab, Lenvatinib, Targeted therapy, tislelizumab, PD-1 inhibitors

Wen Li

Unresectable Hepatocellular Carcinoma

01/24

LIVERPEARL, NCT04595266: Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease

Recruiting

Europe

FOLFOX regimen, Leucovorin/Fluorouracil/Oxaliplatin, Anti-EGFR or Bevacizumab, monoclonal antibody anti EGFR (RASwt) or Bevacizumab (RASmut), LIVERPEARLS-Irinotecan, Chemoembolization of Irinotecan in hydrogel microspheres

Grupo Espanol Multidisciplinario del Cancer Digestivo

Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer

01/24

01/25

NCT05170503: Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma

Recruiting

RoW

Sintilimab

Sun Yat-sen University

Esophagogastric Junction Adenocarcinoma

01/24

01/29

NCT05193292: Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

Not yet recruiting

RoW

Camrelizumab, Trastuzumab, XELOX regimen, mFOLFOX6 regimen, FOLFIRI regimen, mXELIRI regimen, mIRIS regimen

Fudan University

Colorectal Neoplasms, Intestinal Neoplasms

01/24

01/25

SILAR, NCT05450029: Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer

Recruiting

RoW

Sintilimab, Chemoradiotherapy and PD1 inhibitor

Yanhong Deng, GeneCast Biotechnology Co., Ltd.

Rectal Cancer

01/24

01/27

NCT05177068: Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Recruiting

RoW

fruquintinib + sintilimab + SOX

Henan Cancer Hospital

Gastric Cancer

01/24

01/25

NCT05435313: Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

Active, not recruiting

RoW

HAIC, Fruquintinib, Tislelizumab, Raltitrexed, Oxaliplatin, Irinotecan

Fudan University

Colorectal Cancer

01/24

02/24

NCT05132504: Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

Recruiting

Pembrolizumab, keytruda, Folfirinox, mFolfirinox

Baylor College of Medicine, Merck Sharp & Dohme LLC, The Methodist Hospital Research Institute

Pancreatic Ductal Adenocarcinoma

07/24

12/24

NCT06166589: Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

Not yet recruiting

RoW

Zimberelimab, Oxaliplatin, S-1, Irinotecan

Shanghai Zhongshan Hospital

Previously AG Chemotherapy Treated Pancreatic Cancer

01/26

01/27

NCT06197438: Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

Not yet recruiting

Tislelizumab, Oxaliplatin, Levo-Leucovorin, 5-fluorouracil, Irinotecan Hydrochloride, Paclitaxel

Fujian Cancer Hospital

Gastric Cancer

04/24

04/25

NCT06266832: The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

Recruiting

RoW

Adebrelimab, SHR-1316, Oxaliplatin, Capecitabine, Short-course Radiation, Biopsy

Sir Run Run Shaw Hospital

Rectal Adenocarcinoma

01/25

12/27

NCT06244225: HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Recruiting

RoW

Donafenib； Sintilimab； HAIC

Wuhan Union Hospital, China

Hepatocellular Carcinoma

01/26

01/28

NCT06157996: Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Recruiting

RoW

lenvatinib and tislelizumab plus CapeOX chemotherapy, tislelizumab plus CapeOX chemotherapy

Nanfang Hospital, Southern Medical University

Gastric Cancer

08/26

Averectal, NCT03503630: Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma

Active, not recruiting

RoW

COMPOUND 2055269, Radiation Therapy, mFOLFOX, Total Mesorectal Excision

Ali Shamseddine, Merck KGaA, Darmstadt, Germany, Phoenix Clinical Research

Locally Advanced Rectal Cancer

03/21

07/24

NCT06230471: Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Recruiting

RoW

Pembrolizumab,Lenvatinib and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）, Pembrolizumab and Lenvatinib, Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）

Peking Union Medical College Hospital

Biliary Tract Neoplasms Immunotherapy

12/24

12/25

ChiCTR2400079718: Single-arm, single-center, exploratory Phase II clinical study of Envafolimab combined with chemoradiotherapy in the treatment of locally advanced pMMR/MSS rectal cancer

Recruiting

China

Enweida (envafolimab) - 3DMed, Tracon Pharma, Ascletis, capecitabine - Generic mfg.

Yunnan Cancer Hospital, Beijing Bethune Charitable Foundation

pMMR/MSS locally advanced rectal cancer

PTCA199-7, NCT06149689: mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer

Recruiting

RoW

mFOLFIRINOX plus radiotherapy, mFOLFIRINOX plus IMRT

Fudan University

Pancreatic Adenocarcinoma

10/25

10/26

NCT05251662: Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Recruiting

RoW

Sintilimab, IBI305, Bevacizumab Biosimilar, GEMOX

Tianjin Medical University Cancer Institute and Hospital

Intrahepatic Cholangiocarcinoma

01/24

01/25

NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer

Completed

124

Europe

Aflibercept + mLV5FU2, mFOLFOX7

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi

Colorectal Cancer

02/24

NeoOPTIMIZE, NCT04539808: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Recruiting

Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Losartan Potassium, Cozaar, losartan, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Resection, Surgical Resection, Diagnostic Imaging, Medical Imaging, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection

OHSU Knight Cancer Institute, Oregon Health and Science University

Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8

04/25

10/25

NCT05186558: Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Not yet recruiting

RoW

penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin

The First Affiliated Hospital with Nanjing Medical University

Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type

01/24

02/26

NCT06231017: Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer

Recruiting

RoW

Adebrelimab + Cetuximab+ Chemotherapy

The First Affiliated Hospital of Zhengzhou University

Metastatic Colorectal Cancer

01/25

01/26

NCT06151262: A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer

Recruiting

RoW

Trilaciclib+mFOLFIRINOX, G1T28, CDK 4/6 inhibitor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Pancreatic Cancer

05/25

10/26

2021-005326-23: Evaluation of the efficacy of donepezil in the treatment of oxaliplatin-induced peripheral neuropathy EVALUATION DE L’EFFICACITE DU DONEPEZIL DANS LE TRAITEMENT DES NEUROPATHIES PERIPHERIQUES INDUITES PAR L’OXALIPLATINE

Not yet recruiting

Europe

DONEPEZIL, Tablet, Donepezil

CHU de Clermont-Ferrand, Institut National du Cancer (INCa)

Oxaliplatine-induced peripheral neuropathy Neuropathie périphérique induite par l'oxaliplatine, Oxaliplatine-induced peripheral neuropathy Neuropathie périphérique induite par l'oxaliplatine, Diseases [C] - Nervous System Diseases [C10]

CRAFTER, NCT05358704: Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer () for Rectal Cancer

Recruiting

combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil), prior to surgery

Rutgers, The State University of New Jersey

Cancer of Rectum

01/24

NCT05430698: PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma

Recruiting

RoW

PD-1antibody plus GEMOX

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Perihilar Cholangiocarcinoma

01/24

10/25

NCT04757363: A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

Active, not recruiting

regorafenib, nivolumab, FOLFOX chemotherapy with oxaliplatin

Memorial Sloan Kettering Cancer Center, Bayer, Bristol-Myers Squibb

Esophagogastric Cancer, HER2-Negative

02/25

NCT05665023: Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma

Recruiting

RoW

Bevacizumab + modified FOLFIRINOX

Yonsei University

Mucinous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

02/24

02/25

NCT06227325: Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

Not yet recruiting

RoW

RC48 combined with Sintilimab and XELOX, Disitamab vedotin combined with Sintilimab and XELOX

Henan Cancer Hospital

Gastric Cancer

12/24

12/25

EGIA-003, NCT06225843: Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis

Recruiting

Canada

Sotevtamab, AB-16B5, FOLFOX

Alethia Biotherapeutics

Metastatic Colorectal Cancer

03/25

06/25

FOLFORINOX SBA, NCT06278545: Trial Evaluating Modified FOLFIRINOX and Modified FOLFOX in the Treatment of Locally Advanced or Metastatic Small Bowel Adenocarcinoma

Recruiting

130

Europe

modified FOLFORINOX, Modified FOLFOX

Centre Hospitalier Universitaire Dijon

Locally Advanced or Metastatic Small Bowel Adenocarcinoma

02/27

02/29

NCT05731726: Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

Recruiting

RoW

Serplilumab, HLX10, Capecitabine, Xeloda, Oxaliplatin, OHP, Celecoxib, Given PO

Zhejiang University

pMMR, MSS, MSI-L, Locally Advanced Rectal Carcinoma

02/24

02/25

NCT06213519: HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis

Not yet recruiting

S-1, Oxaliplatin sintilimab HIPEC

Sichuan University

Peritoneal Metastases, Gastric Cancer

05/27

06/27

NCT06254521: The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer

Recruiting

RoW

Tislelizumab combined with chemotherapy

First Affiliated Hospital of Guangxi Medical University

Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III

12/24

12/27

NCT04505553: Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

Active, not recruiting

Acupuncture Therapy, Acupuncture, Acupressure Therapy, acupressure, Ischemic Compression, Oral Cryotherapy, Questionnaire Administration, Quality-of-Life Assessment, Quality of Life Assessment

University of Washington, National Cancer Institute (NCI), The Safeway Foundation

Appendix Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Malignant Digestive System Neoplasm, Pancreatic Carcinoma, Rectal Carcinoma, Small Intestinal Carcinoma, Anal Carcinoma, Digestive System Carcinoma, Digestive System Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor

03/24

09/24

REVERCE II, NCT04117945: Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Active, not recruiting

Cetuximab, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Irinotecan, Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, MoAb ABX-EGF, Monoclonal Antibody ABX-EGF, Vectibix, Regorafenib, BAY 73-4506, Stivarga

Academic and Community Cancer Research United, National Cancer Institute (NCI)

BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, NRAS Gene Mutation Negative, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8

02/24

03/25

NCT04840264: Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction

Recruiting

RoW

Docetaxel, Oxaliplatin, Fluorouracil, 5-FU

Sixth Affiliated Hospital, Sun Yat-sen University

Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis

12/26

06/27

NCT04294264: TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

Active, not recruiting

Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Trifluridine and Tipiracil Hydrochloride, Lonsurf, TAS 102, TAS-102, Tipiracil Hydrochloride Mixture with Trifluridine, Trifluridine/Tipiracil, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102

Rutgers, The State University of New Jersey, National Cancer Institute (NCI)

Metastatic Colorectal Carcinoma, Recurrent Colon Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colon Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7

03/24

IMAGINE, NCT04062656 / 2018-000383-28: Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG

Jan 2023 - Dec 2023 : Expiry in EU

Active, not recruiting

Europe

Nivolumab, Opdivo, relatlimab, BMS-986016 (Bristol Myer´s Squibb), Oxaliplatin, ELOXATIN, Docetaxel, Taxotere, 5-Fluorouracil (5-FU), Adrucil, Folic acid (FA), Leucovorin

University Hospital, Essen, GWT-TUD GmbH

Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction

03/24

06/25

GASPAR, NCT04736485 / 2020-004497-21: Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)

Active, not recruiting

Europe

perioperative treatment

Centre Francois Baclesse, National Cancer Institute, France

Gastric Cancer by AJCC V8 Stage, Resectable Carcinoma

03/24

03/27

NCT05753163: Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II Study

Recruiting

RoW

HAIC-FOLFOX combined with Sintilimab and Regorafenib

Fudan University

Colorectal Liver Metastasis

03/24

03/25

DeFianCe, NCT05480306: Phase 2 Study of DKN-01 in Colorectal Cancer

	Oct 2023 - Mar 2024 : Initial PFS data from DeFianCe trial in combination with bevacizumab and chemotherapy for colorectal cancer
	Jul 2023 - Sep 2023 : Initial ORR data from DeFianCe trial in combination with bevacizumab and chemotherapy for colorectal cancer

Recruiting

200

Europe, US, RoW

DKN-01, LY2812176, FOLFIRI, Bevacizumab, FOLFOX

Leap Therapeutics, Inc.

Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer, Colorectal Cancer Metastatic

10/25

NCT05524155: Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis

Not yet recruiting

HAIC, Hepatic Artery Infusion Chemotherapy, Sintilimab, IBI308, Regorafenib

Tianjin Medical University Cancer Institute and Hospital

Colorectal Cancer, Liver Metastasis

03/24

12/24

NCT06046963: Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites

Recruiting

RoW

Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion, Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected

Zhejiang Cancer Hospital

Gastric Cancer, Peritoneal Metastases, Ascites, Malignant

03/24

03/25

NCT04962958: Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Not yet recruiting

RoW

Hepatic arterial infusion chemotherapy, HAIC, Folfox Protocol, Oxaliplatin , fluorouracil, and leucovorin, Donafenib

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Meng Chao Hepatobiliary Hospital of Fujian Medical University, Huashan Hospital, The Second Affiliated Hospital of Harbin Medical University

Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms, Digestive System Neoplasms, Antineoplastic Agents, Donafenib, Fluorouracil, Oxaliplatin, Antimetabolites

03/24

08/24

NCT05839470: Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Recruiting

RoW

cadonilimab, irinotecan, Oxaliplatin, leucovorin or levoleucovorin, 5-FU

Fujian Cancer Hospital

Colorectal Cancer

03/24

03/25

NCT06310473: Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Not yet recruiting

RoW

Cadonilimab, AK104, Oxaliplatin, Capecitabine

Nanfang Hospital, Southern Medical University

Gastric Cancer, Esophagogastric Junction Cancer

03/25

03/28

CASINOs, NCT06204094: Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer

Not yet recruiting

RoW

node-sparing short-course radiotherapy, Sintilimab, IBI308, Capecitabine, Oxaliplatin, TME surgery, total mesorectal excision, watch and wait, WW

Jinhua Central Hospital

Locally Advanced Rectal Cancer

09/25

09/28

NCT06287398: Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL

Not yet recruiting

Epcoritamab

Australasian Leukaemia and Lymphoma Group

DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, DLBCL, Nos Genetic Subtypes, High Grade B-Cell Lymphoma, Not Otherwise Specified, Follicular Large Cell Lymphoma, Relapsed, Follicular Large Cell Lymphoma

11/26

11/31

HAI-TL, NCT06210334: HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus

Not yet recruiting

RoW

Tislelizumab, PD-1, Lenvatinib, TKI

Li Xiao Wei

Hepatocellular Carcinoma With PVTT

07/25

01/26

BIG, NCT06253611: First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

Not yet recruiting

120

Nivolumab, Opdivo, FOLFOX regimen, Leucovorin, fluorouracil, and oxaliplatin, EXL01

GERCOR - Multidisciplinary Oncology Cooperative Group

Gastric Cancer

03/26

03/29

NCT06282445: Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

Recruiting

RoW

Adebrelimab, SHR-1316, Oxaliplatin, Capecitabine, Bevacizumab

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Colorectal Cancer Metastatic

03/25

03/26

TRINITY, NCT06253650: Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease

Recruiting

Europe

Experimental, Control

Gruppo Oncologico del Nord-Ovest

Gastric Cancer, HER2-positive Gastric Cancer

03/27

03/28

NCT06364007: HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC

Recruiting

RoW

HAIC+STRIDE+Len

Sulai Liu

Hepatocellular Carcinoma

12/25

03/26

NCT06362317: Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Recruiting

300

RoW

Toripalimab, Lenvatinib, Gemox Chemotherapy（Gemox or GC）

Peking Union Medical College Hospital

Biliary Tract Neoplasms Immunotherapy

03/25

03/26

NCT06247956: Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer

Recruiting

120

RoW

SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection, Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma

02/25

08/25

NCT03418038: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recruiting

Ascorbic Acid, 2-(1,2-dihydroxyethyl)-4,5-dihydroxy-furan-3-one, Asorbicap, C Vitamin, C-Long, Ce-Vi-Sol, Cecon, Cenolate, Cetane, Cevalin, L-Ascorbic Acid, VIT C, Vitamin C, Vitamin-C, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, JM8, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16-213, VP16, VP-16, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Placebo Administration, Questionnaire Administration, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Ikgdar, Mabtas, Decitabine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Core Biopsy, BIOPSY, CORE, CORE CNB, Core Needle, Core Needle Biopsy, Needle Biopsy, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Echocardiography, EC, ECHO, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), positron emission tomography scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, nuclear magnetic resonance imaging, Structural MRI, sMRI, Central Venous Cannula Insertion, Central venous catheter, Central Venous Catheter Placement, Portacath Placement, Port-a-cath Placement, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT SCAN, tomography

Mayo Clinic, National Cancer Institute (NCI)

Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia

12/25

03/26

NCT06304545: Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

Not yet recruiting

Camrelizumab, SHR-1210, Chemotherapy, Capecitabine or combined oxaliplatin, Radiotherapy, Long-term concurrent chemoradiotherapy

Harbin Medical University

Rectal Cancer

08/26

03/27

GFLIPM, NCT06233877: Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer

Not yet recruiting

G-GLIP plus Mitomycin C

Hirschfeld Oncology

Pancreatic Cancer

01/27

01/28

NCT06208462: Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Recruiting

RoW

Adebrelimab, SHR-1316, Lenvatinib, 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide, Gemcitabine, Difluorodeoxycytidine Hydrochloride, Oxaliplatin, Diaminocyclohexane Oxalatoplatinum

The First Affiliated Hospital with Nanjing Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd.

Intrahepatic Cholangiocarcinoma

01/26

01/27

REVISE, NCT06242418: ctDNA in Adjuvant Chemotherapy of Stage III Colon Cancer ( Trial)

Recruiting

RoW

FOLFOXIRI, XELOX

West China Hospital, GeneCast Biotechnology Co., Ltd.

Colon Cancer

12/25

12/26

NCT05799820: QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

Recruiting

RoW

QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine

Qilu Pharmaceutical Co., Ltd.

Colorectal Carcinoma

03/24

09/25

NCT03997435: FOLFOXIRI With or Without Intensification for Rectal Cancer

Recruiting

RoW

Control arm, Experimental arm

CCTU

Rectal Cancer

12/25

12/26

CONVERSION, NCT03401294: Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.

Not yet recruiting

FOLFOXIRI and Bevacizumab, 5FU, leucovorin, oxaliplatin, irinotecan and bevacizumab

University of Saskatchewan

Metastatic Colorectal Cancer

03/26

NCT05617430: Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma

Recruiting

RoW

HAIC, hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil, leucovorin (FOLFOX) treatment (Q3W), Sintilimab, IBI308, Bevacizumab Biosimilar IBI305, IBI305

Wuhan Union Hospital, China

Hepatocellular Carcinoma

04/24

06/24

NCT06238167: Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC

Not yet recruiting

Tislelizumab, S-1 therapy, low dose SOX therapy

First Affiliated Hospital of Wenzhou Medical University

Gastric Cancer

12/26

12/28

NCT06202716: Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore

Not yet recruiting

RoW

Cadonilimab plus CapeOX chemotherapy

Nanfang Hospital, Southern Medical University

Gastric Cancer

04/26

PTCA199-10, NCT06249321: mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy

Recruiting

RoW

mFOLFIRINOX plus IMRT

Fudan University

Pancreatic Cancer, Radiotherapy

03/26

03/28

NCT06341595: Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM

Recruiting

RoW

Sintilimab, Extraperitoneal radiation therapy, Oxaliplatin, S-1

The First Affiliated Hospital with Nanjing Medical University

Gastric Cancer, Gastric Cancer Metastatic to Regional Lymph Nodes

12/25

12/26

NCT06320301: Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)

Recruiting

RoW

Adebrelimab + GEMOX + TKI, Adebrelimab+ tyrosine kinase inhibitor (TKI) + gemcitabine - oxaliplatin (GEMOX)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Biliary Tract Cancer, Gemox Chemotherapy

02/26

06/26

TORCH-E2, NCT06462053: Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer

Recruiting

134

RoW

Short-course radiotherapy, SCRT, PD-1 antibody (Toripalimab), Toripalimab, Long-course radiotherapy, LCRT, Oxaliplatin, Capecitabine, Xeloda

Fudan University

Early Low Rectal Cancer

04/26

03/27

NCT06283121: A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer

Not yet recruiting

BioTTT001 intraperitoneal infusion, SOX regimen, toripalimab

China Medical University, China, Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Gastric Cancer, Metastatic

11/27

NCT06196697: AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Recruiting

RoW

Cadonilimab, AK104, Ivonescimab, AK112, XELOX, oxaliplatin and capecitabine, SOX, oxaliplatin and Tegafur

Harbin Medical University

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

01/27

03/27

NCT06363825: A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

Recruiting

RoW

camrelizumab, apatinib

Fujian Medical University

Advanced Hepatocellular Carcinoma

04/26

05/27

ChiCTR2100045241: Lenvatinib Combined with Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria: a Phase II, Single-arm, Prospective Study

Recruiting

Lenvatinib combined with Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin

Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital, No

Hepatocellular Carcinoma

NCT04028167: Induction FLOT With CROSS CRT for Esophageal Cancer

Recruiting

Sequential FLOT followed by chemoradiation

University of Colorado, Denver, National Cancer Institute (NCI)

Adenocarcinoma Esophagus, Adenocarcinoma of the Gastroesophageal Junction

04/25

04/26

RAIC, NCT05307198: Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC

Recruiting

RoW

Oxaliplatin, Rectectomy, Capecitabine, Anti-PD-1 monoclonal antibody, Sintilimab

Second Affiliated Hospital, School of Medicine, Zhejiang University

Rectal Neoplasms

04/24

04/25

IRB-2024-311, NCT06374901: Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.

Not yet recruiting

134

RoW

Tislelizumab, SOX/XELOX

Xiangdong Cheng, Liaoning Tumor Hospital & Institute, Shanxi Province Cancer Hospital, Sichuan Cancer Hospital and Research Institute, The Second Affiliated Hospital of Harbin Medical University

Gastric Cancer

03/26

03/28

NCT03488667: Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Active, not recruiting

Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab

University of Kansas Medical Center, Merck Sharp & Dohme LLC

Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma

04/24

04/25

HCC-HAIC-001, NCT06375317: HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure

Not yet recruiting

PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets

Yehua Shen

HCC - Hepatocellular Carcinoma

04/26

10/26

NCT00492999: Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Active, not recruiting

dexamethasone, floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin

Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)

Colorectal Cancer, Metastatic Cancer

05/25

PANCREAS, NCT04452461: Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery

Recruiting

Canada

mFOLFIRINOX, 5-FU, leucovorin, oxaliplatin, Gemcitabine / Nab-paclitaxel, gemcitabine / abraxane

Hamilton Health Sciences Corporation

Pancreatic Adenocarcinoma

05/24

05/26

NCT04594772: Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

Recruiting

Folfirinox, 5-fluorouracil, irinotecan and oxaliplatin, Gemcitabine, gemcitabine and nab-paclitaxel, radiation therapy, Pancreatectomy

University of Cincinnati

Pancreas Cancer

05/24

01/26

NCT05466019: A Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ)

Recruiting

RoW

Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)

The First Hospital of Jilin University

PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer

05/24

12/24

BASKETâ…¡, NCT04895137: mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC

Recruiting

RoW

mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations, mFOLFOX6+Bevacizumab+Sintilimab treatment combinations

Sixth Affiliated Hospital, Sun Yat-sen University

Colorectal Cancer, Immunotherapy

05/24

NCT05575635: Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC

Not yet recruiting

fruquintinib + concurrent radiotherapy + chemotherapy

Henan Provincial People's Hospital

Rectal Cancer

05/24

11/25

NCT05640726: The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Not yet recruiting

PD-1, SCRT, Bevacizumab, Oxaliplatin, Calcium folinate, 5-fluorouracil

Fujian Cancer Hospital

Rectal Cancer

05/24

05/26

OBU-HCC-II-001, NCT06405061: A Prospective, Single-arm, Multicenter Phase II Clinical Study of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma

Not yet recruiting

RoW

Adebrelimab, Bevacizumab, HAIC

Tianjin Medical University Cancer Institute and Hospital

Adebrelimab, Hepatocellular Carcinoma

05/25

08/27

RELIEVE -01, NCT06390982: Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: Study

Not yet recruiting

Radiotherapy, Tislelizumab, Capecitabine, Oxaliplatin

Fudan University, Shanghai Zhongshan Hospital, Shanghai Changzheng Hospital, Huadong Hospital, RenJi Hospital, The Fourth Hospital of Hebei Medical University, First Hospital of China Medical University, Liaoning Cancer Hospital & Institute

RECTAL NEOPLASMS, Rectal Cancer

12/25

12/28

NeoCHIC, NCT06368141: Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer

Not yet recruiting

RoW

Serplulimab, HLX10, Capecitabine, Oxaliplatin

Ruijin Hospital

Colon Cancer

02/26

04/26

Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Not yet recruiting

120

Europe

Dostarlimab, Chemotherapy

UNICANCER, National Cancer Institute, France, GlaxoSmithKline

Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma

10/28

09/30

NCT06423937: Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer

Not yet recruiting

129

RoW

combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab

Fudan University

Colorectal Cancer

07/26

07/27

NCT06405139: Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine as Conversion Therapy of Locally Advanced Colorectal Cancer

Recruiting

RoW

Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine, Nanoliposomal Irinotecan, Oxaliplatin, Capecitabine

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Colorectal Cancer

04/26

04/27

NCT06397235: DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

Recruiting

130

RoW

DEB-TACE+HAIC, DEB-TACE

Second Affiliated Hospital of Guangzhou Medical University

Hepatocellular Carcinoma Non-resectable

04/27

04/28

NCT04931420: Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

Not yet recruiting

Standard of Care Chemotherapy, Video-Assisted Thoracic Surgery (VATS), thoracoscopy, thoracoscopic surgery or pleuroscopy,, Lobectomy, Consolidative Radiation, intensification therapy, postremission therapy., Ablation Treatment, Resection or Excision, Peritonectomy, Transarterial Radioembolization, TARE

University of Chicago

Metastatic Cancer, Foregut Carcinoid Tumor, Gastric Adenocarcinoma, Gallbladder Adenocarcinoma, Liver Cancer, GI Cancer, GI Carcinoma, Lung Cancer

05/26

11/27

TORCH-LE, NCT06455124: Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer

Recruiting

RoW

Radiation, PD-1 antibody, Toripalimab, Capecitabine, Xeloda, Oxaliplatin

Fudan University

Rectal Cancer

06/26

12/29

ChiCTR2300073934: Prospective study of oxaliplatin combined with retitrexed continuous hepatic artery infusion in the treatment of recurrent liver cancer after liver transplantation

Recruiting

None

the third affiliated hospital of Sun Yat-sen university; the third affiliated hospital of Sun Yat-sen university, Self financing by researchers

Hepatocellular Carcinoma

NCT05086627: Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

Recruiting

100

RoW

Tislelizumab, Short-course radiotherapy, Capecitabine+Oxaliplatin

Hebei Medical University Fourth Hospital

Locally Advanced Rectal Cancer

05/24

05/26



	Diseases Companies Products Productz Mechanisms of Action Sites